BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32151375)

  • 1. Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome.
    Levy T; Migdan Z; Aleohin N; Ben-Shem ; Peled O; Tal O; Elyashiv O
    Gynecol Oncol; 2020 May; 157(2):392-397. PubMed ID: 32151375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
    Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
    Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
    Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
    Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.
    Kim JS; Liang MI; Prendergast EN; Alldredge J; Datta A; Hurteau JA; Kirschner CV; Rodriguez G; Vogel TJ; Brooks RA; Cass I; Cohen JG; Penner KR; Wang CE; Diaz Moore ES
    Int J Gynecol Cancer; 2019 Sep; 29(7):1156-1163. PubMed ID: 31352365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
    Jamieson A; Sykes P; Eva L; Bergzoll C; Simcock B
    Gynecol Oncol; 2017 Aug; 146(2):273-278. PubMed ID: 28549816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated lymph node recurrence in epithelial ovarian cancer - management and outcome.
    Jain V; Debnath S; Sharma A; Kamboj M; Mohanty A; Rawal S
    J Visc Surg; 2023 Jun; 160(3):169-179. PubMed ID: 36564260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer.
    Song N; Gao Y
    Int J Gynecol Cancer; 2019 May; 29(4):761-767. PubMed ID: 30850437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated lymph node recurrence in epithelial ovarian cancer: Recurrence with better prognosis?
    Delangle R; Rossard L; Cirier J; Delvallée J; Bendifallah S; Touboul C; Collinet P; Coutant C; Akladios C; Lavoué V; Bolze PA; Huchon C; Bricou A; Canlorbe G; Ballester M; Darai E; Body G; Ouldamer L;
    Eur J Obstet Gynecol Reprod Biol; 2020 Jun; 249():64-69. PubMed ID: 32381349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
    Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
    Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.
    Petrillo M; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Vizzielli G; Pedone Anchora L; Nero C; Margariti PA; Scambia G
    Gynecol Oncol; 2013 Oct; 131(1):36-41. PubMed ID: 23791829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
    Ferrero A; Ditto A; Giorda G; Gadducci A; Greggi S; Daniele A; Fuso L; Panuccio E; Scaffa C; Raspagliesi F; Sismondi P; Biglia N
    Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
    Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
    Bizzarri N; du Bois A; Fruscio R; De Felice F; De Iaco P; Casarin J; Vizza E; Chiantera V; Corrado G; Cianci S; Magni S; Ferrari D; Giuliani D; Harter P; Ataseven B; Bommert M; Perrone AM; Scambia G; Fagotti A
    Gynecol Oncol; 2021 Jan; 160(1):56-63. PubMed ID: 33168305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
    Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
    Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.
    Vincent L; Jankowski C; Ouldamer L; Ballester M; Bendifallah S; Bolze PA; Akladios C; Costaz H; Lavoué V; Canlorbe G; Collinet P; Touboul C; Huchon C; Bricou A; Dridi S; Padéano MM; Bengrine L; Arnould L; Coutant C;
    Eur J Surg Oncol; 2020 Sep; 46(9):1689-1696. PubMed ID: 32417154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer.
    Berretta R; Capozzi VA; Sozzi G; Volpi L; Ceni V; Melpignano M; Giordano G; Marchesi F; Monica M; Di Serio M; Riccò M; Ceccaroni M
    Arch Gynecol Obstet; 2018 Apr; 297(4):997-1004. PubMed ID: 29380107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence patterns in patients with abnormal cardiophrenic lymph nodes at ovarian cancer diagnosis.
    Larish A; Mert I; McGree M; Weaver A; Sheedy S; Cilby W
    Int J Gynecol Cancer; 2020 Apr; 30(4):504-508. PubMed ID: 31953350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome.
    Legge F; Petrillo M; Adamo V; Pisconti S; Scambia G; Ferrandina G
    BMC Cancer; 2008 Dec; 8():367. PubMed ID: 19077269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.